Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: Approaches are presented for temporary highlighting of selected fields of a document. For example, a user can select which fields of a document or class of documents he wishes to have highlighted. The user can also select (a) when he wishes the selected fields to be highlighted, for example, if a field exceeds a threshold and/or (b) how he wishes the selected fields to be highlighted, e.g., overlay the field with a contrasting color. When the user performs a specified action, for example, opens a document, the selected field is selectively highlighted according to the rules for when and how to highlight the selected field. This can help a user quickly recognize important fields in the context of the document.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Abstract: A synchronization protocol is provided that can be used to resolve synchronization errors encountered while trying to synchronize versions of data objects between a client device and a remote computing system. The protocol includes a client device, in an offline processing mode, handling user interface (“UI”) manipulation actions on one or more UI elements of one or more UI screens. The handling of the UI manipulation actions modifies or creates a local version of a data object stored on the client device. The UI manipulation actions are stored by the client device and sent to the remote computing system. The client device receives a synchronization error notification from the remote computing system. After receiving the notification, the client device displays, in one of the UI screens, the local version of the data object and one or more indications of a synchronization error.

Abstract: A method includes initiating, at backend server, a process for synchronization of a data record stored locally on a client computing device with a corresponding data record stored in a backend database. The synchronization process includes comparing the hash value of the data record stored locally on the client computing device and the hash value of the corresponding data record stored in the backend database, and based on the comparing, sending information about the corresponding data record stored in the backend database to the client computing device, if needed for updating the data record stored locally on the client computing device.

Abstract: A synchronization protocol is used to transfer information from a remote computing system to a client device. At the remote computing system, synchronization configuration information is retrieved. The synchronization configuration includes a synchronization rule specifying a data object schema to which the synchronization rule will apply, truncation criteria, and a truncation threshold. The truncation threshold specifies a maximum amount of shared data object instances of the data object schema that may be sent to the client device during a synchronization task. The remote computing system analyzes metadata of a plurality of shared data object instances of the data object schema. Relevant shared data object instances of the plurality of shared data object instances meeting the truncation criteria are determined by the remote computing system. The relevant data object instances are sent from the remote computing system to the client device until the truncation threshold is met.

Abstract: A method for synchronizing business data in a networked or cloud computing arrangement between a model-based business application server and a client-side computing device, which can operate in either online or offline modes, involves providing, on the client-side computing device, a copy of a property model used on the server-side by the application server to process business data. The method further includes, when the client-side computing device is offline, processing locally stored business data on the client-side computing device with reference to the copy of the property model, and later, when the client-side computing device comes online, synchronizing the locally stored business data on the client-side computing device and business data stored on the application server side.

Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Abstract: A system and method for modeling properties of data and events of a business application is presented. The system include a user interface frontend system that displays a user interface, and a user interface backend system that hosts a business application that generates the user interface for display in the user interface frontend system. The system further includes an enterprise service framework comprising one or more data processors that define one or more properties of data and/or events related to the business application, and model each of the one or more properties as a data field of the business application. A dynamic properties calculator includes one or more data processors that access a set of transformation logic representing data transformation rules for each of the data fields of the business application, and apply the transformation rules to the data fields that represent the one or more properties.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Abstract: The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: Access by a user to a database layer, is governed by modeled authorization checking implemented with authorization objects present in an overlying application layer. At design time, the authorization checking is modeled as part of an existing user interface (UI) model, which may conform to a Model, View, and Control (MVC) design pattern. Authorization objects created during design time, are stored in a meta data repository. At runtime, an authorization engine references the authorization objects and the operations supported by those authorization objects. The authorization check is thus implemented centrally in the UI framework itself using this modeled information. Embodiments avoid complexity, potential lack of internal consistency, and low visibility of conventional de-centralized authorization checking schemes that rely upon a plurality of enforcement points hard-coded at multiple locations within application logic.